Literature DB >> 7528215

Identification of the urokinase receptor as an adhesion receptor for vitronectin.

Y Wei1, D A Waltz, N Rao, R J Drummond, S Rosenberg, H A Chapman.   

Abstract

Urokinase receptors, expressed on surfaces of many cell types, focus to the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. We now report that the urokinase receptor (uPAR) is also a high affinity (Kd < 30 nM) receptor for vitronectin. Recombinant uPAR binds vitronectin in the absence of urokinase, but vitronectin binding is promoted by concurrent receptor binding of either urokinase or fragments thereof containing its uPAR binding domain. Stable epithelial cell transfectants expressing membrane-anchored uPAR, but not cells expressing soluble uPAR, become strongly adhesive with altered morphology in the absence of urokinase. These observations identify a new class of vitronectin receptor and imply a duality in function for the receptor that intrinsically links matrix adhesion to regulation of protease activity. Increases in urokinase receptor expression known to be associated with cellular activation and malignant transformation could modulate cellular trafficking and function by promoting attachment to vitronectin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528215

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  140 in total

1.  Migration of keratinocytes through tunnels of digested fibrin.

Authors:  V Ronfard; Y Barrandon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of CD14 and urokinase receptor.

Authors:  H Li; W S Wong
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

3.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

4.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

5.  Role of integrin alpha(v)beta3 in the early phase of liver metastasis: PET and IVM analyses.

Authors:  Hironori Kikkawa; Masako Kaihou; Natsuko Horaguchi; Takayuki Uchida; Hidetoshi Imafuku; Ayano Takiguchi; Yukako Yamazaki; Chieko Koike; Ryoko Kuruto; Takeharu Kakiuchi; Hideo Tsukada; Yoshikazu Takada; Nariaki Matsuura; Naoto Oku
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

6.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Construction of antisense RNA expression plasmid for u-PAR and its transfection to highly invasive PC-3M cell subclones.

Authors:  Guoning Liao; Qingfen Li; Youmei Feng; Yaozu Deng; Zhuoya Li; Feili Gong; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

8.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

9.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

Review 10.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.